Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of maridebart cafraglutide in adults with type 2 diabetes mellitus
2024-513539-25-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Nov 2024
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Maridebart cafraglutide dose arm(s) with Placebo arm (2 arms). Primary endpoint: Change from baseline to week 24 in hemoglobin A1c. Planned start Nov 2024; status: authorised.
02
Drugs
maridebart cafraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-513539-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513539-25-00.